I am a Consultant Urological Surgeon at University Hospitals of Leicester (GMC 7456289), with a specialist focus on prostate cancer, robotic prostatectomy and robotic pelvic uro-oncology.

My private practice is based at Spire Leicester Hospital and Spire Cambridge Lea Hospital. My main clinical interest is the diagnosis and surgical treatment of prostate cancer, particularly robot-assisted radical prostatectomy, transperineal prostate biopsy, and careful decision-making for men with newly diagnosed or suspected prostate cancer.

I hold a first class BSc (University of Manchester), MBChB (University of Bristol Medicine), MSc (from the University of Oxford), and FRCS Urol and FEBU qualifications. I am a Fellow of the Royal College of Surgeons of England and the European Board of Urology, and I am on the GMC Specialist Register. I completed a post-CCT fellowship in robotic pelvic uro-oncology at Oxford University Hospitals and have also undertaken robotic surgical training at ORSI Academy in Belgium. Earlier in my training, I worked as an invited research fellow at the Global Robotics Institute in Florida with Dr Vipul Patel.

My practice is focused on high-volume prostate cancer surgery. I perform robot-assisted radical prostatectomy, including nerve-sparing and modified Retzius-sparing techniques where appropriate. The aim is always to balance cancer control with recovery of urinary continence and sexual function. I also perform robotic cystectomy, transperineal prostate biopsies, TURP for benign prostate enlargement, TURBT for bladder tumours, and core diagnostic urological procedures.

I take a data-driven and outcomes-focused approach to surgery. I keep a detailed log of operative complexity, cancer clearance, functional recovery and patient outcomes, so that advice can be based on real results rather than vague promises. In prostate cancer surgery, detail matters: the MRI, biopsy findings, anatomy, tumour position, nerve-sparing plan, reconstruction and recovery pathway all need to be considered together.

Alongside my clinical work, I am actively involved in prostate cancer research. My academic interests include robotic prostatectomy, nerve-sparing surgery, prostate MRI, image-guided diagnosis, focal therapy, active surveillance, PSMA-PET imaging, prostate cancer recurrence, continence recovery and the use of better data to guide treatment decisions.

I have authored more than 25 PubMed-indexed publications with over 1,000 citations, with work published in journals including European Urology, BJU International, European Urology Oncology, Journal of Robotic Surgery and Journal of Clinical Urology. My research has included systematic reviews, clinical outcome studies, imaging-led prostate cancer pathways and technical work in robotic prostate surgery.

My published work includes research on focal therapy for localised prostate cancer, active surveillance, salvage robot-assisted radical prostatectomy, artificial urinary sphincter complications after prostate cancer treatment, continence outcomes after robotic prostatectomy, selective nerve-sparing in high-risk prostate cancer, neurovascular bundle-sparing techniques, indocyanine green fluorescence in robotic urology, and PSMA-PET detected recurrence after radical prostatectomy.

I am also involved in prostate cancer service development and patient support. I serve as a Trustee, Consultant Urological Surgeon and PROSTaid Prostate Cancer Centre Lead, supporting work that improves information, counselling and practical help for men and families affected by prostate cancer.

Current and developing projects include work on improving prostate cancer pathways, imaging-led risk assessment, MRI and histology correlation, and data-driven approaches to surgical planning. I am particularly interested in how prostate MRI, pathology, genomics and operative outcomes can be brought together to improve treatment selection and make prostate cancer care more precise.

My approach with patients is straightforward. I explain the diagnosis clearly, discuss all suitable options, and avoid pushing treatment where surveillance or another approach is more appropriate. When surgery is the right option, I aim to plan it carefully, operate meticulously and support recovery properly.

Prostate cancer care should not feel like being pushed through a system. Patients deserve clear information, honest advice and a surgeon who knows the details.